Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/21548331.1994.11443046 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Circulating tumor DNA in head and neck squamous cell carcinoma-current status and future prospects.
Acad Oncol
December 2024
Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL 60637, USA.
Squamous cell carcinoma (SCC) is the most common malignancy of the head and neck. Stagnating survival rates in recent decades, despite advances in the treatment paradigms, surveillance technologies, and multidisciplinary care, leave clinicians with a need for better options for screening, risk-stratifying, and monitoring patients. A growing proportion of patients with HPV-associated SCC have improved outcomes but continue to have a heterogenous response to treatment.
View Article and Find Full Text PDFA High-Fat Diet Induces Epigenetic 1-Carbon Metabolism, Homocystinuria, and Renal-Dependent HFpEF.
Nutrients
January 2025
Department of Physiology, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Background/objectives: Chronic gut dysbiosis due to a high-fat diet (HFD) instigates cardiac remodeling and heart failure with preserved ejection fraction (HFpEF), in particular, kidney/volume-dependent HFpEF. Studies report that although mitochondrial ATP citrate lyase (ACLY) supports cardiac function, it decreases more in human HFpEF than HFrEF. Interestingly, ACLY synthesizes lipids and creates hyperlipidemia.
View Article and Find Full Text PDFNext-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches.
Cancers (Basel)
January 2025
Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, and, with only 15-20% of HCC patients being suitable for potentially curative treatments, the vast majority of patients with HCC ultimately require systemic therapy. For decades, the choice of effective systemic therapy for HCC remained sparse. In recent years, after the combination of atezolizumab and bevacizumab demonstrated superior overall survival over the first-line standard, sorafenib, there has been a major therapeutic paradigm shift to immunotherapy-based regimens for HCC.
View Article and Find Full Text PDFFunctional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancer.
Clin Transl Med
February 2025
Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York, USA.
Background: The goal of precision oncology is to find effective therapeutics for every patient. Through the inclusion of emerging therapeutics in a high-throughput drug screening platform, our functional genomics pipeline inverts the common paradigm to identify patient populations that are likely to benefit from novel therapeutic strategies.
Approach: Utilizing drug screening data across a panel of 46 cancer cell lines from 11 tumor lineages, we identified an ovarian cancer-specific sensitivity to the first-in-class CRL4 inhibitors KH-4-43 and 33-11.
Evidence of a persistent altered neural state in people with fibromyalgia syndrome during functional MRI studies and its relationship with pain and anxiety.
PLoS One
January 2025
Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada.
Altered neural signaling in fibromyalgia syndrome (FM) was investigated with functional magnetic resonance imaging (fMRI). We employed a novel fMRI network analysis method, Structural and Physiological Modeling (SAPM), which provides more detailed information than previous methods. The study involved brain fMRI data from participants with FM (N = 22) and a control group (HC, N = 18), acquired during a noxious stimulation paradigm.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!